Express News | UroGen Highlights Results From Study On Durability Of Response From Post-Commercialization Of JELMYTO Titled 'Durability of Response of UGN-101: Longitudinal Follow-Up of Multicenter Study'

BenzingaJan 22 08:08 ET

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population With Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

UroGen PharmaJan 22 00:00 ET

Express News | UroGen Pharma Shares Are Trading Higher After the Company Reported Its ENVISION Trial Results in the February Issue of The Journal of Urology

BenzingaJan 15 08:08 ET

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

BenzingaJan 14 06:00 ET

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session

BenzingaJan 10 08:44 ET

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)

Yahoo FinanceDec 31, 2024 07:06 ET